Zhongchao Inc.
No enriched coverage for $ZCMD in the last 7 days.
No SEC Form 4 filings for $ZCMD in the last 30 days.
A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.
Zhongchao Inc. (NASDAQ:ZCMD) shares jumped about 210% to $3.44 in after-hours Thursday after closing at $1.11. The move followed a 1-for-3 share consolidation effective Monday, approved by shareholders and the board to help maintain its Nasdaq listing. Trading volume rose to 23.99M vs 1.58M average; market cap is about $1.28M.
Zhongchao Inc. (ZCMD) said it will conduct a 1-for-31 share consolidation effective June 8, 2026, to stay compliant with Nasdaq Capital Market listing requirements. According to the company, 31 Class A (and 31 Class B) shares will be combined into one share, with fractional shares rounded up. It reported 79,685,696 Class A and 624,972 Class B shares outstanding before consolidation, versus about 2,570,507 and 20,161 after. The stock was down 16.02% at $0.030.
Recent ZCMD coverage spans market movers and financial news.
Reverse-split compliance action is the immediate catalyst behind the outsized move, but it can also signal ongoing listing risk.
The after-hours surge is tied to the newly effective 1-for-3 reverse split, which can mechanically distort per-share price and liquidity/positioning.
Reverse split risk event that can affect liquidity, volatility, and near-term sentiment while preserving listing status.
Zhongchao Inc. (NASDAQ: ZCMD) is seeking shareholder approval for a proposal to implement reverse stock splits with ratios between 2:1 and 250:1 over three years, aiming to meet Nasdaq's minimum bid price requirements. The company's shares closed at $0.62 on November 25, 2025.
alphai scores every news story that mentions ZCMD with an AI model for sentiment and relevance, and aggregates insider trades from Zhongchao Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.
3 min readZhongchao Inc. (NASDAQ:ZCMD) shares jumped about 210% to $3.44 in after-hours Thursday after closing at $1.11. The move followed a 1-for-3 share consolidation effective Monday, approved by shareholders and the board to help maintain its Nasdaq listing. Trading volume rose to 23.99M vs 1.58M average; market cap is about $1.28M.
3 min readZhongchao Inc. (ZCMD) said it will conduct a 1-for-31 share consolidation effective June 8, 2026, to stay compliant with Nasdaq Capital Market listing requirements. According to the company, 31 Class A (and 31 Class B) shares will be combined into one share, with fractional shares rounded up. It reported 79,685,696 Class A and 624,972 Class B shares outstanding before consolidation, versus about 2,570,507 and 20,161 after. The stock was down 16.02% at $0.030.
3 min readZhongchao Inc. (NASDAQ: ZCMD) is seeking shareholder approval for an amended proposal allowing its board broad authority to implement one or multiple reverse stock splits over three years, with a cumulative ratio between 2:1 and 250:1. This move is primarily aimed at satisfying Nasdaq's minimum bid price requirement, as the company's Class A shares closed at US$0.62 on November 25, 2025. The company has adjourned shareholder meetings to allow more time for consideration of these proposals, which also include a significant increase in authorized share capital.
3 min read
